Establishes a grant program to fund drug development trials for ibogaine to treat opioid use disorder and other conditions.

The bill establishes a grant program to fund drug development trials for ibogaine, aiming to secure FDA approval for treating opioid use disorder, co-occurring substance use disorder, and other neurological or mental health conditions. The Health and Human Services Commission will administer the program, establish trial sites, and select an institutional review board. Applicants must match state funding and submit detailed trial plans, including recruitment, screening, and administration protocols. The bill also outlines provisions for ibogaine treatment administration if approved by the FDA.

Establishes a grant program to fund drug development trials for ibogaine to treat opioid use disorder and other conditions.

The bill establishes a grant program to fund drug development trials for ibogaine, aiming to secure FDA approval for treating opioid use disorder, co-occurring substance use disorder, and other neurological or mental health conditions. The Health and Human Services Commission will administer the program, establish trial sites, and select an institutional review board. Applicants must match state funding and submit detailed trial plans, including recruitment, screening, and administration protocols. The bill also outlines provisions for ibogaine treatment administration if approved by the FDA.